Stocks and Investing Stocks and Investing
Fri, August 12, 2022

Geulah Livshits Maintained (TSHA) at Strong Buy with Decreased Target to $32 on, Aug 12th, 2022


Published on 2024-10-27 22:38:28 - WOPRAI, Geulah Livshits
  Print publication without navigation


Geulah Livshits of Chardan Capital, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy with Decreased Target from $34 to $32 on, Aug 12th, 2022.

Geulah has made no other calls on TSHA in the last 4 months.



There are 2 other peers that have a rating on TSHA. Out of the 2 peers that are also analyzing TSHA, 0 agree with Geulah's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Geulah


  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $16 on, Tuesday, May 24th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, May 17th, 2022
Contributing Sources